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Clinical and molecular characteristics differ between right-sided and left-sided colorectal
cancer (CRC). This study aimed to clarify the correlation between CRC sidedness and
tumor immunity.
Methods
A total of 102 patients who underwent curative colectomy for stage II/III CRC were included
in this study. The expression of programmed cell death (PD)-1, PD1-ligand 1 (PD-L1), fork-
head box P3 (Foxp3), transforming growth factor (TGF)-β, and indoleamine-pyrrole 2,3-
dioxygenase (IDO) were examined using immunohistochemistry and the relationships
between sidedness and several prognostic factors were examined.
Results
Clinicopathological factors were not significantly different between right- and left-sided
CRC. The tumor immunity-related molecule PD-L1 was more highly expressed in right-
sided than in left-sided CRC (62.9% vs. 30.6%, p<0.01). No significant difference was found
in overall survival (OS) and disease-free survival (DFS) by sidedness. PD-1 and Foxp3
expression were significant prognostic factors for OS. Lymph node metastasis (N), lym-
phatic invasion (ly), and PD-L1 expression were significant prognostic factors for DFS. In
right-sided CRC, IDO-positive patients had a poor OS (p<0.05), and IDO was the only inde-
pendent prognostic indicator for OS. N and venous invasion were identified as independent
prognostic indicators for DFS. In left-sided CRC, univariate analysis identified PD-1, PD-L1,
and Foxp3 expression as significant predictors of poor OS. Multivariate analysis confirmed
PD-L1 expression as an independent prognostic indicator. N, ly, and PD-L1 expression lev-
els were identified as significant predictors of poor DFS.
Conclusions
The prognostic factors were IDO in right-sided CRC and PD-L1 and Foxp3 in left-sided
CRC. These findings indicated that tumor immunity might play different roles depending
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upon sidedness. Tumor location may be an important factor to consider when assessing
immune response and therapeutic decisions in CRC patients.
Introduction
Colorectal cancer (CRC) is one of the most common cancers in both men and women world-
wide. Research in CRC has been focused on providing more personalized treatment based on
genetic and molecular mechanisms of carcinogenesis. Accumulating evidence indicates that
CRC shows differences in pathogenesis, molecular pathways, and prognosis depending on the
sidedness [1].
Chromosomal instability is associated with 60%-70% of CRC and frequently observed in
left-sided CRC. Furthermore, Kirsten rat sarcoma viral oncogene homolog (KRAS) and p53
mutations have been characterized as left-sided CRC [2]. In contrast, microsatellite instability
(MSI)-high, B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation, and CpG island
methylator phenotype (CIMP)-high are often characterized as right-sided CRC [1, 3]. The
seminal phase II trial reported that metastatic CRC with deficient DNA mismatch repair
(dMMR) and MSI-high responds to programmed cell death 1 (PD-1) inhibitors while CRCs
with proficient MMR and microsatellite stable (MSS) do not [4]. We previously reported that
PD-1 and PD-1 ligand 1 (PD-L1) expression levels were associated with poor prognosis and
correlated with transforming growth factor (TGF)-β and forkhead box P3 (Foxp3) expression
in CRC patients [5]. Previous report revealed reported immune cell-specific PD-L1 and PD-1
expression as prognostic factors depending on the sidedness [6]. However, the characteristics
of tumor immunity have not been investigated in relation to the tumor sidedness. Therefore,
the aim of this study was to reveal the correlation of CRC sidedness with tumor immunity.
Methods
Patients
For 5 years from April 2004 to April 2009, 102 patients who underwent curative colectomy for
stage II/III CRC in the Tokushima University Hospital were included in this study. Tumors
located in the cecum and ascending and transverse colon up to the splenic flexure were defined
as right sided, whereas those of the descending colon, sigmoid colon, and rectum were defined
as left sided [1].
There were 69 men and 34 women, with a mean age of 68.7 (range, 41–90) years. The mean
follow-up period were 60 (range 11–158) months. Fifty-two patients underwent adjuvant che-
motherapy. Factors were defined according to the 8th edition of the Japanese Classification of
Colorectal Carcinoma. Each participant provided written, informed consent prior to participa-
tion in this study, and this study was authorized in advance by the institutional review board
of the University of Tokushima Graduate School of Medical Science (Approved #2347).
Immunohistochemistry
Tissue samples were formalin fixed, paraffin embedded, cut into 5 μm-thick serial sections,
which were dewaxed, deparaffinized in xylene, and rehydrated using a series of graded alcohol
concentrations. Samples were boiled for 20 min in a microwave oven in citrate buffer (pH 6.0)
for antigen retrieval. Endogenous peroxidases were blocked with 0.3% hydrogen peroxide for
30 min, followed by incubation in 5% goat serum for 60 min to prevent nonspecific antigen
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binding. The slides were then incubated with primary antibodies overnight at 4˚C. The follow-
ing primary antibodies and dilutions were used: mouse monoclonal antibody against PD-1
(AF1086, 1:40; R&D Systems, Minneapolis, MN, USA), rabbit monoclonal antibody against
PD-L1 (ab174838, 1:100; Abcam, Cambridge, UK), and mouse monoclonal antibodies against
Foxp3 (ab20034, 1:100; Abcam), IDO (ab71276, 1:50; Abcam), and TGF-β (sc-146, 1:100;
Santa Cruz). Secondary antibody binding was detected using Histofine SAB-PO (Nichirei) for
PD-1 and EnVision Dual Link System-horseradish peroxidase (HRP, DAKO) for PD-L1,
Foxp3, IDO, and TGF-β. A secondary peroxidase-labeled polymer conjugated to goat anti-
mouse immunoglobulins was applied for 60 min. The sections were developed with 3,3-diami-
nobenzidine (DAB) and counterstained with Mayer’s hematoxylin. Each slide was dehydrated
using a graded series of alcohol concentrations and covered with a coverslip. The presence of
positive cells on each slide was determined by a pathologist in a blinded manner.
As followed out previous experiment [7], PD-1 positivity was recorded when> 40% mono-
nuclear cells in tumor tissue were stained in a ×400 high-power field of the tumor tissue section
(Fig 1A). PD-L1 expression was predominantly located in the cytoplasm (Fig 1B). Staining
intensity was scored as follows: 0, no staining; 1+, weak staining; 2+, moderate staining; and 3+,
strong staining. Distribution was scored according to the percentage of PD-L1-positive cancer
cells and then divided into quartiles as follows based on percentage staining: none, 0–5%; 1+,
6–25%; 2+, 26–50%; 3+, 51–75%; and 4+, 76–100%. A total score of> 3+ was defined as
PD-L1-positive expression in tumor cells [7, 8]. We recorded Foxp3 positivity by counting
more than 10 Foxp3-stained mononuclear cells in tumor tissue under ×200 high-power field
(Fig 1C) [9]. TGF-β expression was predominantly located in the cytoplasm. TGF-β positivity
was recorded when> 10% of the tumor cells were stained in the tumor tissue section (Fig 1D)
Fig 1. Immunohistochemistry. a. PD-1-positive expression in mononuclear cells in tumor tissue (x 400). b. PD-L1-positive expression
in tumor cells (x 200). c. Foxp3-positive expression in mononuclear cells in tumor tissue (x 400). d. TGF-β-positive expression in tumor
cells (x 200). e. IDO-positive expression in tumor cells (x 200).
https://doi.org/10.1371/journal.pone.0240408.g001
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[10]. IDO expression was predominantly located in the cytoplasm. Staining intensity was scored
as follows: 0, no staining, 1+, weak; 2+, moderate; and 3+, strong. Distribution was scored
according to the percentage of IDO-positive cancer cells and then divided into quartiles based
on staining as follows: none, 0, 0–9%; 1+, 10–50%; 2+, 51–80%; 3+, 51–80%; and 4+, 81–100%.
A total score of> 4+ was defined as IDO-positive expression in tumor cells (Fig 1E) [11].
Statistical analysis
All statistical analyses were performed using JMP 8.0.1 (SAS, Cary, NC, USA). Continuous vari-
ables were compared using the Mann–Whitney U test, and categorical data were compared using
chi-square (λ2) test. Survival curves were calculated using the Kaplan–Meier method and compared
using log-rank tests. The prognostic potentials of the parameters were analyzed using univariate
analysis. Relative risk and 95% confidence intervals (CI) were estimated using the Cox proportional
hazards model with stepwise forward selection. Statistical significance was defined as p<0.05.
Results
Patients and tumor characteristics
The characteristics of patients according to the tumor sidedness are shown in Table 1. There
were 27 patients of right-sided CRC and 75 patients of left-sided CRC. No significant differ-
ence was found in the patient and tumor characteristics depending on the sidedness. In terms
of tumor immunity, PD-L1 expression was positively correlated with the sidedness of tumor.
PD-L1 expression was higher in right-sided CRC than in left-sided CRC (62.9% vs. 30.6%,
p<0.01). However, there was no significant difference in expression of PD-1, TGF-β, Foxp3,
and IDO between the two groups.
Prognostic factors for CRC
In this study, univariate analysis identified expression of PD-1 (p = 0.02), PD-L1 (p = 0.01),
and Foxp3 (p = 0.04) as significant prognostic factors for overall survival (OS) (Table 2). The
Table 1. Patient and tumor characteristics.
Variables Right-sided (n = 27) Left-sided (n = 75) p-value
<Patient characteristics>
Sex (male/female) 15/12 54/21 0.11
Age (year) 71±10 67±10 0.08
Adjuvant chemotherapy (-/+) 13:14 37:38 0.91
<Tumor characteristics>
T stage (T1,2/T3,4) 9:18 34:41 0.27
Lymph node metastasis (-/+) 14:13 37:38 0.82
Primary tumor size (cm) 5.1±2.6 4.5±2.0 0.25
Tumor differentiation (tub1,2/muc, por) 5:22 6:69 0.13
Lymphatic invasion (-/+) 15:12 48:27 0.43
Venous invasion (-/+) 13:14 36:39 0.98
<Immune molecules>
PD-1 (-/+) 19:8 54:21 0.87
PD-L1 (-/+) 10:17 52:23 0.003
TGF-β (-/+) 9:18 34:41 0.27
Foxp3 (-/+) 9:18 32:43 0.39
IDO (-/+) 19:8 52:23 0.92
https://doi.org/10.1371/journal.pone.0240408.t001
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OS rates was significantly poorer in the PD-1-positive group than in the PD-1-negative group
(5-year OS rate, 78.7% vs. 93.6%, respectively). Furthermore, the PD-L1 and Foxp3 positive
group showed poor survival compared to those of negative group (5-year OS rate, PD-L1:
76.3% vs. 93.0%, p = 0.01, Foxp3: 83.8% vs. 97.1%, p = 0.04, respectively).
Regarding the disease-free survival (DFS), univariate analysis identified N (p = 0.001), lym-
phatic invasion (ly, p = 0.003), PD-L1 expression (p = 0.03), and Foxp3 expression (P = 0.04)
as significant prognostic factors (Table 2). The PD-L1 and Foxp3 positive group showed poor
survival compared to those of negative group (5-year DFS rate, PD-L1: 66.8% vs. 81.7%,
p = 0.04, Foxp3: 66.8% vs. 81.7%, p = 0.03, respectively).
Multivariate analysis confirmed N (p = 0.01) as an independent risk factor for recurrence
(relative risks of 3.39, Table 3).
Prognostic factors for right-sided CRC
In the right-side evaluation, univariate analysis identified only IDO expression (p = 0.03, Fig
2) as a significant prognostic factor for OS (Table 4). The OS rates was significantly poorer in
Table 2. Univariate analysis of prognostic factors for colorectal cancer (CRC).
Variables 5-year survival rate (%) p-value
<OS>
Age (<65 years/�65 years) 89.6/89.0 0.95
Sex (male/female) 93.1/81.1 0.05
Tumor differentiation (tub1,2/muc, por) 89.4/87.5 0.83
T stage (T1,2/T3,4) 83.3/89.7 0.13
Lymph node metastasis (-/+) 93.9/83.9 0.14
Lymphatic invasion (-/+) 91.4/86.0 0.28
Venous invasion (-/+) 85.0/89.6 0.99
PD-1 (-/+) 93.6/78.7 0.02
PD-L1 (-/+) 93.0/76.3 0.01
TGF-β (-/+) 89.7/88.9 0.84
Foxp3 (-/+) 97.1/83.8 0.04
IDO (-/+) 90.4/86.8 0.25
Adjuvant chemotherapy (-/+) 89.2/89.2 0.67
Tumor location (right/left) 91.7/88.7 0.58
<DFS>
Age (<65 years/�65 years) 78.4/77.8 0.64
Sex (male/female) 80.7/72.7 0.29
Tumor differentiation (tub1,2/muc, por) 76.7/90.9 0.32
T stage (T1,2/T3,4) 71.4/78.7 0.48
Lymph node metastasis (-/+) 90.8/65.3 0.001
Lymphatic invasion (-/+) 86.4/64.1 0.003
Venous invasion (-/+) 84.2/72.7 0.18
PD-1 (-/+) 77.7/79.1 0.93
PD-L1 (-/+) 81.7/66.8 0.03
TGF-β (-/+) 80.4/76.4 0.72
Foxp3 (-/+) 87.2/71.9 0.04
IDO (-/+) 76.6/72.0 0.14
Adjuvant chemotherapy (-/+) 82.0/69.8 0.21
Tumor location (right/left) 84.8/76.2 0.43
https://doi.org/10.1371/journal.pone.0240408.t002
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the IDO-positive group than in the IDO-negative group (5-year OS rate, 75.0% vs. 100%,
respectively). The PD-1, PD-L1, TGF-β and Foxp3 expression was not prognostic in right-
sided CRC. Multivariate analysis confirmed IDO expression as independent prognostic indica-
tors (relative risks of 1.84, Table 3).
Regarding the DFS, univariate analysis identified N (p = 0.02) and v (p = 0.04) as significant
prognostic factors (Table 4). None of immune marker was prognostic in right-sided CRC.
Multivariate analysis confirmed N (p = 0.01) and v (p = 0.01) as independent risk factors
for recurrence (relative risks of 1.1 and 8.7, respectively, Table 3).
Prognostic factors for left-sided CRC
In the left side evaluation, univariate analysis identified PD-1 expression (p = 0.02), PD-L1
expression (p = 0.03) and Foxp3 expression (p = 0.03) as significant prognostic factors for OS
(Table 5) in left-sided CRC. The OS rates was significantly poorer in the PD-1, PD-L1 and
Foxp3 positive group than in the negative group (5-year OS rate, PD-1: 80.7% vs. 98.1%,
PD-L1: 75.4% vs. 91.4%, Foxp3: 82.7% vs. 96.5%, respectively, Fig 3A–3C).
Regarding the DFS, univariate analysis identified N (p = 0.02), ly (p = 0.007) and PD-L1
(p = 0.04) as significant prognostic factors (Table 5). The DFS rates was significantly poorer in
the PD-L1-positive group than in the PD-L1-negative group (5-year DFS rate, 59.2% vs.
80.4%, respectively). N was identified as an independent prognostic factor for DFS in left-
sided CRC.
Table 3. Multivariate analysis of prognostic factors in colorectal cancer (CRC).
Variables Relative risk 95% CI p-value
CRC
<OS>
PD-1 + 1.70 0.51–5.59 0.38
PD-L1 + 2.88 0.89–9.29 0.08
Foxp3 + 2.88 0.58–14.3 0.15
<DFS>
Lymph node metastasis + 3.39 1.20–9.57 0.01
Lymphatic invasion + 2.28 0.92–5.65 0.06
PD-L1 1.38 0.55–3.45 0.49
Foxp3 + 1.89 0.70–5.13 0.19
Right-sided
<OS>
IDO + 1.84 - 0.03
<DFS>
Lymph node metastasis + 1.10 - 0.01
Venous invasion + 8.70 - 0.01
Left-sided
<OS>
PD-1 + 1.82 0.48–6.82 0.37
PD-L1 + 2.10 0.52–8.42 0.29
Foxp3 + 2.49 0.46–13.6 0.26
<DFS>
Lymph node metastasis + 1.79 - 0.02
Lymphatic invasion + 3.13 0.32–30.5 0.28
PD-L1 + 1.43 0.19–10.5 0.72
https://doi.org/10.1371/journal.pone.0240408.t003
PLOS ONE Sidedness of CRC on tumor immunity
PLOS ONE | https://doi.org/10.1371/journal.pone.0240408 October 12, 2020 6 / 12
Discussion
In this study, we showed the characteristics of immune markers associated with the sidedness
of CRC. In right-sided CRC, PD-L1 was highly expressed than it was in left-sided CRC. In
right-sided CRC, IDO positive group had significantly poor OS than negative group. No
immune markers were related to the DFS. In left-sided CRC, the PD-L1 positive group showed
significantly poor OS and DFS. Furthermore, the PD-1- and Foxp3-positive groups exhibited a
significantly poor OS. This is the first report to show the characteristics of several tumor
immune markers depending on the sidedness of the tumor.
Right-sided CRC was previously reported to have a high malignant potential, poor differen-
tiation, and advanced stage, resulting in a poorer prognosis than that of left-sided CRC [12].
These differences are possibly due to differences in genetics, life-style, and dietary habits [12].
Chromosomal instability is more often observed in left-sided colon cancer than in right-sided,
whereas defective genes include adenomatous polyposis coli (APC) and KRAS deletion [2]. In
contrast, MSI-high, CIMP-high, BRAF mutation, and tumor-infiltrating lymphocytes (TIL)
are characteristic in right-sided CRC [1, 3]. Both MSI and TIL are associated with a better
prognosis and lower recurrence in patients with curative resection [13, 14]. Numerous recent
studies have shown that mismatch repair status predicts the benefit of immune checkpoint
blockade [15] and PD-1 and PD-L1 expression have been reported as predictive markers for
PD-1/PD-L1 blockade. Furthermore, the MSI status correlated with PD-L1 expression in CRC
[16]. PD-L1 expression was significantly higher in MSI-H/TML-high primary tumors from
Fig 2. The overall survival rates in the right sided CRC. Kaplan–Meier analysis of 5-year overall survival for IDO
expression. The OS rates was significantly poorer in the IDO-positive group (n = 9) than in the IDO-negative group
(n = 18) (5-year OS rate, 75.0% vs. 100%, respectively).
https://doi.org/10.1371/journal.pone.0240408.g002
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both left- and right sided CRC. These findings might suggest, at least partly, that the mucosal
immunology differed depending on the sidedness.
PD-1 and PD-L1 play important roles in the regulation of the immune system and the
maintenance of peripheral tolerance through T cell activation and tolerance [17]. We previ-
ously reported PD-1 expression as a predictor of poor prognosis in stage II/III gastric cancer
[7] and CRC [5]. In our experiments, PD-1 was positively correlated with expression of the
transcription factor, Foxp3, which is widely known to be involved in the development and
function of regulatory T-cells (Tregs) [18]. Tregs have shown significant correlations with can-
cer progression and metastasis by inhibiting the T cell response via membrane-bound TGF-β1
[19]. We also previously reported that IDO expression is associated with poor prognosis and
immunotolerance through attenuation of Treg activation in stage III gastric cancer [20]. IDO
is an intracellular enzyme that catabolizes the conversion of tryptophan into kynurenine and is
expressed in various types of human tumors [21]. IDO is expressed by tumor cells and tumor-
draining lymph nodes and causes growth arrest and apoptosis of cytotoxic T and NK cells
[22]. In addition, IDO also induces host Tregs [23] and is correlated with decreased patient
survival [20]. Furthermore, high IDO-expressing tumors showed significantly lower numbers
of TIL than IDO non-expressing tumors did [19, 20]. This is the first report to show the
Table 4. Univariate analysis of prognostic factors for right-sided colorectal cancer (CRC).
Variables 5-year survival rate (%) P-value
<OS >
Age (<65 years/�65 years) 100/88.1 0.34
Sex (male/female) 100/82.5 0.12
Tumor differentiation (tub1,2/muc, por) 89.9/100 0.49
T stage (T1,2/T3,4) 100/91.4 0.76
Lymph node metastasis (-/+) 100/82.1 0.12
Lymphatic invasion (-/+) 100/80.8 0.09
Venous invasion (-/+) 100/83.9 0.15
PD-1 (-/+) 93.3/87.5 0.56
PD-L1 (-/+) 100/78.7 0.06
TGF-β (-/+) 87.5/94.1 0.66
Foxp3 (-/+) 100/87.3 0.29
IDO (-/+) 100/75.0 0.03
Adjuvant chemotherapy (-/+) 91.6/91.6 0.90
<DFS>
Age (<65 years/�65 years) 87.5/83.5 0.79
Sex (male/female) 93.3/75.0 0.19
Tumor differentiation (tub1,2/muc, por) 100/81.5 0.33
T stage (T1,2/T3,4) 100/84.2 0.68
Lymph node metastasis (-/+) 100/68.4 0.02
Lymphatic invasion (-/+) 93.3/72.9 0.16
Venous invasion (-/+) 100/70.7 0.04
PD-1 (-/+) 89.5/75.0 0.35
PD-L1 (-/+) 87.8/80.0 0.49
TGF-β (-/+) 88.9/82.5 0.70
Foxp3 (-/+) 100/76.9 0.13
IDO (-/+) 88.8/75.0 0.29
Adjuvant chemotherapy (-/+) 92.3/77.9 0.35
https://doi.org/10.1371/journal.pone.0240408.t004
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prognostic impact of IDO expression depending on the sidedness. IDO is the only prognostic
factor in right-sided CRC.
A previous study reported the correlation between PD-1/PD-L1 expression and the sided-
ness of tumors. Berntsson et al. reported immune cell-specific PD-L1 expression is prognostic
factor for OS in right-sided and left-sided CRC but not in rectal cancer. These authors also
reported immune cell-specific PD-1 expression as a prognostic factor for OS in right- but not
left-sided colon and rectal cancer. In our study, PD-1 and PD-L1 expression were prognostic
factors for left- but not right-sided CRC. One reason for this observation might be the specific-
ity of the expressing cells. We examined the PD-1 expression in immune cells and PD-L1
expression in tumor cells. Another study investigated the cytotoxic and regulatory T cell
expression in CRC [24]. High Foxp3 expression was an independent prognostic factor only in
patients with rectal cancer, but there was no significant interaction between Foxp3 expression
and sidedness. In our study, Foxp3 was an independent prognostic factor for OS in left-sided
CRC. One possible explanation for this finding is our classification of sidedness (we included
rectal cancer in the left-sided group).
There were some limitations in this study that are worth mentioning. First, since the study
was retrospective based on data from one institute, there may be a potential risk selection bias.
Table 5. Univariate analysis of prognostic factors for left-sided colorectal cancer (CRC).
Variables 5-year survival rate (%) p-value
<OS>
Age (<65 years/�65 years) 87.8/89.8 0.87
Sex (male/female) 91.8/80.4 0.10
Tumor differentiation (tub1,2/muc, por) 89.4/83.3 0.86
T stage (T1,2/T3,4) 80.0/89.3 0.07
Lymph node metastasis (-/+) 91.9/84.8 0.38
Lymphatic invasion (-/+) 89.2/88.2 0.66
Venous invasion (-/+) 85.7/91.6 0.51
PD-1 (-/+) 93.8/75.6 0.02
PD-L1 (-/+) 91.4/75.4 0.03
TGF-β (-/+) 90.6/87.1 0.58
Foxp3 (-/+) 96.5/82.7 0.03
IDO (-/+) 87.8/91.3 0.84
Adjuvant chemotherapy (-/+) 88.8/88.4 0.58
<DFS>
Age (<65 years/�65 years) 77.1/74.8 0.53
Sex (male/female) 78.2/71.4 0.49
Tumor differentiation (tub1,2/muc, por) 75.5/83.3 0.64
T stage (T1,2/T3,4) 66.6/77.1 0.36
Lymph node metastasis (-/+) 87.7/64.8 0.02
Lymphatic invasion (-/+) 84.6/60.8 0.007
Venous invasion (-/+) 78.9/73.7 0.67
PD-1 (-/+) 74.5/80.9 0.59
PD-L1 (-/+) 80.4/59.2 0.04
TGF-β (-/+) 78.4/74.1 0.73
Foxp3 (-/+) 83.9/70.2 0.19
IDO (-/+) 79.9/68.0 0.25
Adjuvant chemotherapy (-/+) 78.9/73.1 0.33
https://doi.org/10.1371/journal.pone.0240408.t005
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The sample size was small. Furthermore, this study only used one analysis method (IHC). The
biomarker expression should be confirmed by determining mRNA levels and the quantifica-
tion of the infiltration levels of immune cell types by Gene set enrichment assay (GSEA) should
be added in prospective studies. Nevertheless, we revealed the different characteristics of
expressed immune molecules in CRC according to the tumor sidedness. However, the detailed
mechanism including MSI status should be investigated in future studies.
In conclusion, this study reports the first comparison of the prognostic relevance of several
immune-related molecules according to sidedness of CRC tumors. While PD-L1 was highly
expressed in right-sided CRC, PD-L1 was the independent prognostic factor for OS and DFS
in left-sided CRC. Furthermore, IDO was the prognostic factor for OS in right-sided CRC and
Foxp3 was the prognostic factor for OS in left-sided CRC. These findings indicated that tumor
location may be an important factor to consider when assessing immune response and thera-
peutic decisions in CRC patients.
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Fig 3. The overall survival rates in the left sided CRC. a. Kaplan–Meier analysis of 5-year overall survival for PD-1expression. The OS rates was significantly poorer in
the PD-1-positive group (n = 21) than in the PD-1-negative group (n = 54) (5-year OS rate, 80.7% vs. 98.1%, respectively). b. Kaplan–Meier analysis of 5-year overall
survival for PD-L1 expression. The OS rates was significantly poorer in the PD-L1-positive group (n = 15) than in the PD-L1-negative group (n = 60) (5-year OS rate,
75.4% vs. 91.4%, respectively). c. Kaplan–Meier analysis of 5-year overall survival for Foxp3 expression. The OS rates was significantly poorer in the Foxp3-positive group
(n = 43) than in the Foxp3-negative group (n = 32) (5-year OS rate, 82.7% vs. 96.5%, respectively).
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